Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)

• Sponsor: Krystal Biotech, Inc. (Industry)
• Overall Status: Not yet recruiting
• CT.gov ID: NCT05735158
• Collaborator: (none)
• Enrollment: 15
• Location: 1
• Arms: 2
• Anticipated Duration (Months): 13
• Patients Per Site Per Month: 1.2

Study Details

Study Description

Brief Summary

KB105-02 is an intrasubject randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of KB105 in children and adults with autosomal recessive congenital ichthyosis (ARCI).

Condition or Disease	Intervention/Treatment	Phase
Autosomal Recessive Ichthyosis	Biological: KB105; Other: Placebo	Phase 2

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 15 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: An intra-participant parallel study. Matched target areas will be randomized within the participant, such that one target area receives KB105 and the other target area will receive placebo. An additional target area may be selected to receive open-label treatment with KB105.An intra-participant parallel study. Matched target areas will be randomized within the participant, such that one target area receives KB105 and the other target area will receive placebo. An additional target area may be selected to receive open-label treatment with KB105.
• Masking: Triple (Participant, Care Provider, Investigator)
• Primary Purpose: Treatment
• Official Title: A Phase 2, Randomized, Placebo-controlled Study of Topical KB105, a Replication-defective, Non-integrating HSV-1 Vector Expressing Human Transglutaminase 1 (TGM1) for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)
• Anticipated Study Start Date: Mar 1, 2023
• Anticipated Primary Completion Date: Mar 1, 2024
• Anticipated Study Completion Date: Apr 1, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: KB105 Weekly topical application	Biological: KB105; Replication-defective, non-integrating HSV-1 vector expressing TGM1 formulated as a topical gel
Placebo Comparator: Placebo Weekly topical application	Other: Placebo; Visually matched excipient gel

Outcome Measures

Primary Outcome Measures

1. Composite Investigator's Global Assessment (IGA) Responder (Comparison of proportion of responder KB105 target areas to responder placebo target areas) [Week 9]

   Responder target areas are defined as: Target areas with ≥2 point reduction from baseline on IGA scaling severity at Week 9 or Target areas with ≥1 point reduction from baseline on IGA scaling severity for 2 consecutive weeks (Week 8 and Week 9)

Secondary Outcome Measures

1. Composite regional Visual Index of Ichthyosis Severity (VIIS) responder (Comparison of proportion of responder KB105 target areas to responder placebo target areas) [Week 9]

   Responder target areas are defined as: Target areas with ≥2 point reduction from baseline on VIIS scaling score at Week 9 or Target areas with ≥1 point reduction from baseline on VIIS scaling score for 2 consecutive weeks (Week 8 and Week 9)

2. Visual Index of Ichthyosis Severity score change from baseline [Up to 11 weeks]

   Change from baseline in regional Visual Index of Ichthyosis Severity (VIIS) scaling scores, where 0 is normal and 4 is severe

3. Investigator's Global Assessment change from baseline [Up to 11 weeks]

   Change from baseline in Investigator's Global Assessment (IGA) scaling severity scores, where 0 is clear and 4 is severe

4. Investigator's Global Assessment (IGA) 2 point responder [Week 9]

   Comparison of proportion of KB105 and placebo target areas with ≥2 point reduction from baseline on IGA scaling severity at Week 9

5. Investigator's Global Assessment (IGA) 1 point responder [Week 9]

   Comparison of proportion of KB105 and placebo target areas with ≥1 point reduction from baseline on IGA scaling severity for 2 consecutive weeks (Week 8 and Week 9)

6. Visual Index of Ichthyosis Severity (VIIS) 2 point responder [Week 9]

   Comparison of proportion of KB105 and placebo target areas with ≥2 point reduction from baseline on regional VIIS scaling severity at Week 9

7. Visual Index of Ichthyosis Severity (VIIS) 2 point responder [Week 9]

   Comparison of proportion of KB105 and placebo target areas with ≥1 point reduction from baseline on regional VIIS scaling severity for 2 consecutive weeks (Week 8 and Week 9)

Eligibility Criteria

Criteria

• Ages Eligible for Study: 6 Months and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Key Inclusion Criteria:

1. Subject, or legally authorized representative, must be willing and able to give informed consent/assent

2. Aged ≥6 months

3. A genetically confirmed diagnosis of TGM1-deficient ARCI

4. Clinical diagnosis of lamellar ichthyosis

5. Two target areas located on similar anatomical regions with the same scaling severity by IGA and scaling severity ≥3

6. Subjects taking systemic retinoids must be on a stable regimen for at least 4 weeks and agree to continue to take the medication consistently throughout the study. If the subject prefers to withhold systemic retinoids during the study, then a minimum 4-week washout period is required

7. Clinically stable and in good general health

Key Exclusion Criteria:

1. Subject has a physical condition or other dermatological disorder (e.g., atopic, seborrheic, or contact dermatitis, psoriasis, tinea infections, etc.) which, in the Investigator's opinion, might impair evaluation of the target areas or which exposes the subject to unacceptable risk by study participation

2. Participation in another clinical study or treatment with an investigational agent within 30 days or 5 half-lives, whichever is longer

3. Any condition or illness (including a history or current evidence of substance abuse or dependence) that, in the opinion of the Investigator, would impact a subject's ability to complete all study-related procedures and/or poses an additional risk to the assessment of safety of KB105

4. Women who are pregnant or nursing

5. Subject who is unwilling to comply with contraception requirements per protocol

6. Subject is known to be noncompliant or is unlikely to comply with the requirements of the study protocol in the opinion of the Investigator

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Mission Dermatology	Rancho Santa Margarita	California	United States	92688

Sponsors and Collaborators

• Krystal Biotech, Inc.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Krystal Biotech, Inc.
• ClinicalTrials.gov Identifier: NCT05735158
• Other Study ID Numbers: KB105-02
• First Posted: Feb 21, 2023
• Last Update Posted: Feb 23, 2023
• Last Verified: Feb 1, 2023

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Ichthyosis; Ichthyosis, Lamellar; Ichthyosiform Erythroderma, Congenital

Study Results

No Results Posted as of Feb 23, 2023